These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 19089580)
41. Cutaneous side-effects of treatment of chronic hepatitis C by interferon alfa and ribavirin. Kerl K; Negro F; Lübbe J Br J Dermatol; 2003 Sep; 149(3):656. PubMed ID: 14511009 [No Abstract] [Full Text] [Related]
42. [Onset of type 1 diabetes mellitus during combination therapy of chronic hepatitis C with interferon-alpha and ribavirin]. Christensen UB; Krogsgaard K Ugeskr Laeger; 2004 Mar; 166(11):1024-5. PubMed ID: 15049242 [No Abstract] [Full Text] [Related]
44. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy. Gordon A; Menahem S; Mitchell J; Jenkins P; Dowling J; Roberts SK Nephrol Dial Transplant; 2004 Aug; 19(8):2155. PubMed ID: 15252182 [No Abstract] [Full Text] [Related]
45. Pegylated interferon-associated retinopathy is frequent in hepatitis C virus patients with hypertension and justifies ophthalmologic screening. Vujosevic S; Tempesta D; Noventa F; Midena E; Sebastiani G Hepatology; 2012 Aug; 56(2):455-63. PubMed ID: 22331668 [TBL] [Abstract][Full Text] [Related]
46. Development of myasthenia gravis during treatment of chronic hepatitis C with interferon-alpha and ribavirin. Weegink CJ; Chamuleau RA; Reesink HW; Molenaar DS J Gastroenterol; 2001 Oct; 36(10):723-4. PubMed ID: 11686485 [No Abstract] [Full Text] [Related]
47. Meyerson's phenomenon induced by interferon-alfa plus ribavirin in hepatitis C infection. Girard C; Bessis D; Blatìre V; Guilhou JJ; Guillot B Br J Dermatol; 2005 Jan; 152(1):182-3. PubMed ID: 15656829 [No Abstract] [Full Text] [Related]
48. [Interferon-related retinopathy in a man with chronic hepatitis C]. Viennet A; Glatre F; Bacin F J Fr Ophtalmol; 2009 Sep; 32(7):505-10. PubMed ID: 19592135 [TBL] [Abstract][Full Text] [Related]
49. [Patient with HCV chronic hepatitis who has subcutaneous nodules after finishing treatment with pegylated interferon]. Salgado Ordóñez F; Manteca González R; Palacios Rodríguez S; Godoy Guerrero M Rev Clin Esp; 2005 Dec; 205(12):621-2. PubMed ID: 16527184 [No Abstract] [Full Text] [Related]
50. Epiretinal membrane development during interferon treatment. Kargi SH; Oz O; Ustündağ Y; Firat E Can J Ophthalmol; 2003 Dec; 38(7):610-2. PubMed ID: 14740807 [No Abstract] [Full Text] [Related]
51. Leukocytoclastic vasculitis during pegylated interferon and ribavirin treatment of hepatitis C virus infection. Adişen E; Dizbay M; Hizel K; Ilter N Indian J Dermatol Venereol Leprol; 2008; 74(1):60-2. PubMed ID: 18187830 [No Abstract] [Full Text] [Related]
52. Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation. Chisholm JA; Williams G; Spence E; Parks S; Keating D; Gavin M; Mills PR Aliment Pharmacol Ther; 2005 Mar; 21(6):723-32. PubMed ID: 15771758 [TBL] [Abstract][Full Text] [Related]
53. Peginterferon and ribavirin for hepatitis C. Ben Salem C; Hmouda H; Bouraoui K N Engl J Med; 2007 Mar; 356(12):1270; author reply 1271. PubMed ID: 17380578 [No Abstract] [Full Text] [Related]
54. [A case of vasculitis in chronic hepatitis C patient treated with pegylated interferon alpha-2a and ribavirin]. Kim YH; Han WS; Lee SJ; Oh SN; Choi DW; Byun KS; Yeon JE Korean J Hepatol; 2007 Sep; 13(3):419-22. PubMed ID: 17898559 [TBL] [Abstract][Full Text] [Related]
55. Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C. Bhatti A; McGarrity TJ; Gabbay R Am J Gastroenterol; 2001 Feb; 96(2):604-5. PubMed ID: 11232722 [No Abstract] [Full Text] [Related]
56. Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C. Gergely AE; Lafarge P; Fouchard-Hubert I; Lunel-Fabiani F Hepatology; 2002 May; 35(5):1281-2. PubMed ID: 11981781 [No Abstract] [Full Text] [Related]
57. Risk factors for bacterial infections in HIV/hepatitis C virus-coinfected patients treated with interferon plus ribavirin. Bani-Sadr F; Goderel I; Lapidus N; Driss H; Simon A; Rosenthal E; Morand P; Lunel-Fabiani F; Pol S; Cacoub P; Perronne C; Carrat F; AIDS; 2008 Jul; 22(11):1385-7. PubMed ID: 18580626 [No Abstract] [Full Text] [Related]
58. Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful? Balestrieri C; Serra G; Cauli C; Chessa L; Balestrieri A; Farci P Blood; 2006 Apr; 107(8):3409-10. PubMed ID: 16597599 [No Abstract] [Full Text] [Related]
59. [Dysacusia associated with pegylated-interferon and ribavirin combination therapy during chronic hepatitis C treatment: a report of two cases]. Jia YH; Gao SJ; Nan YM Zhonghua Gan Zang Bing Za Zhi; 2012 Jan; 20(1):67-8. PubMed ID: 22489302 [No Abstract] [Full Text] [Related]
60. [Anterior uveitis in a patient treated with pegylated interferon and ribavirin]. Carneros Martín JA; Fuentes Coronel A; Alvarez Delgado A; González San Martín F Med Clin (Barc); 2003 Mar; 120(9):359. PubMed ID: 12646118 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]